Brokerages expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to post $2.85 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Spero Therapeutics’ earnings, with estimates ranging from $2.70 million to $3.00 million. Spero Therapeutics posted sales of $7.30 million in the same quarter last year, which suggests a negative year-over-year growth rate of 61%. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Spero Therapeutics will report full-year sales of $18.07 million for the current year, with estimates ranging from $17.80 million to $18.34 million. For the next fiscal year, analysts forecast that the firm will report sales of $110.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO – Get Rating) last announced its quarterly earnings results on Thursday, March 31st. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.09). Spero Therapeutics had a negative return on equity of 87.72% and a negative net margin of 491.65%. During the same quarter in the prior year, the firm posted ($0.68) earnings per share.
In other news, major shareholder Aquilo Capital Management, Llc acquired 39,727 shares of the business’s stock in a transaction on Tuesday, April 26th. The shares were acquired at an average price of $5.24 per share, for a total transaction of $208,169.48. Following the completion of the transaction, the insider now directly owns 5,321,231 shares of the company’s stock, valued at approximately $27,883,250.44. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 13.45% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Spero Therapeutics by 1.3% during the third quarter. BlackRock Inc. now owns 1,802,528 shares of the company’s stock valued at $33,185,000 after purchasing an additional 23,706 shares during the period. State Street Corp lifted its stake in Spero Therapeutics by 5.1% in the fourth quarter. State Street Corp now owns 843,955 shares of the company’s stock worth $13,512,000 after acquiring an additional 41,264 shares during the period. Granahan Investment Management Inc. MA lifted its stake in Spero Therapeutics by 67.0% in the third quarter. Granahan Investment Management Inc. MA now owns 555,614 shares of the company’s stock worth $10,229,000 after acquiring an additional 222,975 shares during the period. Geode Capital Management LLC lifted its stake in Spero Therapeutics by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 457,184 shares of the company’s stock worth $7,319,000 after acquiring an additional 12,270 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Spero Therapeutics by 12.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 371,222 shares of the company’s stock worth $5,943,000 after acquiring an additional 41,589 shares during the period. 69.36% of the stock is owned by hedge funds and other institutional investors.
Shares of SPRO opened at $2.07 on Friday. The company’s fifty day moving average is $6.94 and its 200 day moving average is $11.30. Spero Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $19.87. The stock has a market capitalization of $67.80 million, a PE ratio of -0.72 and a beta of 1.87.
Spero Therapeutics Company Profile (Get Rating)
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
- Get a free copy of the StockNews.com research report on Spero Therapeutics (SPRO)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.